Abstract
Objective: Our aim was to investigate the effect of tamoxifen on cervical smear of patients with breast cancer at our clinic. Methods: The data of patients with breast cancer who had received tamoxifen were analyzed between 2006 and 2014, retrospectively. Pap smear results, age, gravidity, parity, smoking status, age of first birth, and detailed gynecologic and obstetric history of patients were noted. Patients who had not received at least one-year tamoxifen therapy and patients without cervicovaginal smear controls or those who left or had received interrupted tamoxifen treatment were excluded. The pap smear results of the tamoxifen and control groups were analyzed. Results: A total of 246 patients (123 in the tamoxifen group and 123 in the control group) were included in this study. None of the patients had cervical squamous intraepithelial lesions and atypical glandular lesions. Atypical squamous cells were significantly higher in the tamoxifen group than in the control group (p=0.03). Conclusion: The use of tamoxifen may be associated with benign squamous atypia in cervical smears. Therefore, pelvic examination and pap smear test are recommended for breast cancer patients annually.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
